Trial · NCT01861951
A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
NCT01861951, Phase 2, Completed, Hannover Medical School
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma. Trials, record NCT01861951. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01861951
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Trial Comparing Two Medications as First Treatment in Elderly Patients With Metastatic or Advanced Soft Tissue Sarcoma
- NCT number
- NCT01861951
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 120 participants, actual
- Lead sponsor
- Hannover Medical School
- Conditions
- Soft Tissue Sarcoma
- Interventions
- Pazopanib, Doxorubicin
- First posted
- 2013-05-24
- Last updated
- 2017-08-21
- Other registries' IDs
- eudract:2011-004168-30
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months | 10 to 40 months | |
| Secondary | Change of rates of neutrophil granulocytopenia grade 4 (Day 1 - End of Trial (4 weeks after last IMP dose)), Change in rates of febrile neutropenia (Day 1 - End of Trial (4 weeks after last IMP dose)) | 10 months up to 40 months | |
| Secondary | Change from date randomization in progression-free rate at 12 weeks. Change from date randomization in progression-free rate at 26 weeks. | 10 months up to 40 months | |
| Secondary | Change from date of randomization in overall survival to date of death (from any cause) | 10 months up to 40 months | |
| Secondary | Change from date of randomization in objective response rate at 12 weeks. Change from date of randomization in objective response rate at 26 weeks. | 10 months up to 40 months | |
| Secondary | Collection of life quality questionnaires (QLQ-C30) at baseline, after 3, 6, 9, 12, 15, 19, and 26 weeks from date of randomization and end of therapy (EOT). Thereafter, assessment will be performed every 12 weeks until progression. | 10 months up to 40 months | |
| Secondary | Geriatric assessments from the date of baseline, after 12 and 26 weeks, and then every 12 weeks until progression | 10 months up to 40 months | |
| Secondary | Change in expression of certain biomarkers in blood to predict either response or resistance to pazopanib from baseline, week 2, day 1 of every cycle, week 19 and 26, end of therapy, and as part of the extension study every 6 weeks. | 10 months up to 40 months | |
| Secondary | Time from date of randomization until the date of first objective documentation of disease progression, treatment failure, or death due to any cause, whichever occurs first. | 10 months up to 40 months | |
| Secondary | Time to onset of response after 6, 12, 19 and 26 weeks from date of randomization | 10 months up to 40 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers4
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01861951
GET https://conductscience.org/api/trials/v1/NCT01861951/registered